FDA: One Lot of Metronidazole Tablets Recalled
Tablets may not contain full amount of active ingredient and not treat infection effectively
FRIDAY, Jan. 7 (HealthDay News) -- The U.S. Food and Drug Administration and Teva Pharmaceuticals have notified health care professionals and consumers of a recall of metronidazole tablets (250 mg, lot #312566, expiration date 05/2012), as the tablets may be underweight and not contain the full amount of active ingredient and patients may not receive the prescribed dose.
Metronidazole is used to treat symptomatic and asymptomatic trichomoniasis, asymptomatic consorts, and amebiasis as well as a variety of anaerobic bacterial infections. The recall was issued because if patients do not receive adequate dosing, the infection may worsen or recur. In some cases of severe infections, patients not receiving the prescribed amount of active ingredient within a single tablet could be at risk for life-threatening complications.
The recalled metronidazole lot was distributed nationwide to wholesalers and retailers. The FDA recommends that consumers with the recalled lot should stop taking the drug and return it to their pharmacy.
According to the FDA, "health care professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program."